MONTREAL, March 23, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD)
("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical
company, announced today acceptance by the Toronto Stock Exchange (the "TSX") to amend the
Company’s previously announced Notice of Intention to Make a Normal Course Issuer Bid ("NCIB")
to
increase the maximum number of common shares (the “Common Shares”) that it intends to
repurchase
for cancellation during the 12-month period ending August 21, 2026, from 3,000,000 Common Shares to 6,190,493
Common
Shares, representing approximately 10% of the public float of Common Shares as at August 8, 2025. All other
terms
and conditions of the NCIB remain unchanged.
The Common Shares may be purchased for cancellation through the facilities of the TSX or through
alternative Canadian trading systems at times and in numbers to be determined by the Company. During the period
from
August 22, 2025 to March 19, 2026 inclusively, the Company purchased 1,767,300 Common Shares through the
facilities
of the TSX and alternative Canadian trading systems at a weighted average price per share of $6.08.
Knight has amended its automatic share purchase plan (“ASPP”) with its broker to
reflect the increased number of Common Shares authorized for repurchase under the amended NCIB. Under the ASPP,
Knight’s broker may repurchase Common Shares which it would ordinarily not be permitted to due to regulatory
restrictions or self-imposed blackout periods.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical
company
focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight
Therapeutics Inc.'s Common Shares trade on TSX under the symbol GUD. For more information about Knight
Therapeutics
Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.
Forward-Looking Statement
This document contains forward-looking statements for Knight Therapeutics Inc. and its
subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties
that
could cause actual results to differ materially from those contemplated by the forward-looking statements.
Knight
Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable
at
the time they were prepared but cautions the reader that these assumptions regarding future events, many of
which
are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect.
Factors and risks which could cause actual results to differ materially from current expectations are discussed
in
Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year
ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc.
disclaims
any intention or obligation to update or revise any forward-looking statements, whether as a result of new
information or future events, except as required by law.
CONTACT INFORMATION: